Startup genital warts vaccine developer Virolab loses CEO and CFO

Virolab Inc. Chairman Ricardo Rosales will take over as president and CEO, the startup genital warts vaccine developer said in a Securities and Exchange Commission filing Friday, replacing James A.D. Smith. Smith, the former president and CEO of Genelabs Technologies, resigned Aug. 5 for personal reasons, according to the filing, and Chief Financial Officer Matthew Loar left Aug. 13. Its executive vice president of regulatory affairs and quality,Mohammed Salem, left the company in January to become vice president of global regulatory coordination at Fresenius Medical Care in Waltham, Mass.